179 related articles for article (PubMed ID: 21177828)
1. Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.
Kyle KA; Willett TL; Baggio LL; Drucker DJ; Grynpas MD
Endocrinology; 2011 Feb; 152(2):457-67. PubMed ID: 21177828
[TBL] [Abstract][Full Text] [Related]
2. Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
Cusick T; Mu J; Pennypacker BL; Li Z; Scott KR; Shen X; Fisher JE; Langdon RB; Kimmel DB; Zhang BB; Glantschnig H
Diabetes Obes Metab; 2013 Oct; 15(10):954-7. PubMed ID: 23551951
[TBL] [Abstract][Full Text] [Related]
3. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Sauvé M; Ban K; Momen MA; Zhou YQ; Henkelman RM; Husain M; Drucker DJ
Diabetes; 2010 Apr; 59(4):1063-73. PubMed ID: 20097729
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice.
Varin EM; Hanson AA; Beaudry JL; Nguyen MA; Cao X; Baggio LL; Mulvihill EE; Drucker DJ
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663193
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
Bailey CJ; Green BD; Flatt PR
Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.
Smith SY; Samadfam R; Chouinard L; Awori M; Bénardeau A; Bauss F; Guldberg RE; Sebokova E; Wright MB
J Bone Miner Metab; 2015 Nov; 33(6):625-41. PubMed ID: 25534548
[TBL] [Abstract][Full Text] [Related]
9. The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.
Gallagher EJ; Sun H; Kornhauser C; Tobin-Hess A; Epstein S; Yakar S; LeRoith D
Diabetes Metab Res Rev; 2014 Mar; 30(3):191-200. PubMed ID: 24023014
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
11. DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Glorie L; Behets GJ; Baerts L; De Meester I; D'Haese PC; Verhulst A
Am J Physiol Endocrinol Metab; 2014 Sep; 307(5):E447-55. PubMed ID: 25053403
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
Pham DQ; Nogid A; Plakogiannis R
Am J Health Syst Pharm; 2008 Mar; 65(6):521-31. PubMed ID: 18319497
[TBL] [Abstract][Full Text] [Related]
14. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 inhibitor and PPARγ agonist restore the loss of CA1 dendritic spines in obese insulin-resistant rats.
Sripetchwandee J; Pipatpiboon N; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Arch Med Res; 2014 Oct; 45(7):547-52. PubMed ID: 25281415
[TBL] [Abstract][Full Text] [Related]
16. Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
Lenski M; Kazakov A; Marx N; Böhm M; Laufs U
J Mol Cell Cardiol; 2011 Dec; 51(6):906-18. PubMed ID: 21871459
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
18. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats.
Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin.
Lyseng-Williamson KA
Drugs; 2007; 67(4):587-97. PubMed ID: 17352516
[TBL] [Abstract][Full Text] [Related]
20. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Takai S; Sakonjo H; Jin D
J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
